[{"id":"aa674b47-a2ff-421c-bdff-f7efb3e13a9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02043288","created_at":"2021-01-18T09:23:07.507Z","updated_at":"2024-07-02T16:36:45.983Z","phase":"Phase 3","brief_title":"Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer","source_id_and_acronym":"NCT02043288","lead_sponsor":"Orient Europharma Co., Ltd.","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Nanoplatin (demplatin pegraglumer)"],"overall_status":"Completed","enrollment":" Enrollment 310","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2020-04-15"},{"id":"fde23e67-3de2-49dc-aa61-ea030413cf15","acronym":"","url":"https://clinicaltrials.gov/study/NCT02240238","created_at":"2021-01-18T10:30:41.375Z","updated_at":"2024-07-02T16:36:49.398Z","phase":"Phase 1b/2","brief_title":"Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer","source_id_and_acronym":"NCT02240238","lead_sponsor":"NanoCarrier Co., Ltd.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Nanoplatin (demplatin pegraglumer)"],"overall_status":"Completed","enrollment":" Enrollment 209","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 05/06/2019","primary_completion_date":" 05/06/2019","study_txt":" Completion: 05/06/2019","study_completion_date":" 05/06/2019","last_update_posted":"2020-02-28"}]